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Abstract 
Background: Endometriosis is a chronic gynecological inflammatory disease characterized by the presence of func-
tional endometrial glands and stroma outside of the uterine cavity. It affects 7–10% of women of reproductive age 
and up to 50% of women with infertility. The current gold standard for the diagnosis combines laparoscopic evalua-
tion and biopsy of the visualized lesions. However, laparoscopy requires general anesthesia and developed surgical 
skills and it has a high procedural cost. In addition, it is associated with the risk, although rare, of potential intraopera-
tive or postoperative complications. To date, several noninvasive biomarkers have been proposed; however, no defi-
nite diagnostic biomarker is yet available. The aim of this study was to characterize the CM proteome in patients with 
endometriosis using high resolution mass spectrometry—based proteomics, implemented by bioinformatic tools for 
quantitative analysis, in order to investigate the pathophysiological mechanisms of endometriosis.
Methods: Cervical mucus samples were collected from patients affected by endometriosis and fertile controls. An 
aliquot of the soluble acidic fraction of each cervical mucus sample, corresponding to 0.5 mg of total protein, was 
left to digest with sequencing grade modified porcine trypsin. The peptides were analyzed by LC–MS/MS on a high 
resolution Orbitrap Elite mass spectrometer and data were evaluated using bioinformatic tools.
Results: We aimed at the first total profiling of the cervical mucus proteome in endometriosis. From the list of 
identified proteins, we detected a number of differentially expressed proteins, including some functionally significant 
proteins. Six proteins were quantitatively increased in endometriosis, almost all being involved in the inflammatory 
pattern. Nine proteins were quantitatively reduced in endometriosis, including some proteins related with local innate 
immunity (CRISP-3 and Pglyrp1) and protection against oxidative stress (HSPB1). Fifteen proteins were not detected in 
endometriosis samples including certain proteins involved in antimicrobial activity (SLURP1 and KLK13) and related to 
seminal plasma liquefaction and male fertility (KLK13).
Conclusions: This is the first application of high resolution mass spectrometry—based proteomics aimed in detect-
ing an array of proteins in CM to be proposed for the noninvasive diagnosis of endometriosis. This chronic disease 
presents in CM an inflammatory protein pattern.
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Background
Endometriosis is a chronic gynecological inflammatory 
disease characterized by the presence of functional endo-
metrial glands and stroma outside of the uterine cav-
ity [1] that affects 7–10% of women of reproductive age 
and up to 50% of women with infertility [2]. Many stud-
ies report lower fertility rates in women with endome-
triosis compared to patients free from this disease. Many 
mechanisms have been suggested to explain the decrease 
in fertility of these women, such as altered folliculo-
genesis [3], poor oocyte quality [4], luteal phase defects 
[5], sperm damage [6], embryo implantation failure [7], 
abnormal embryogenesis [8]. Studies reported that endo-
metriosis could interfere with the receptivity of eutopic 
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endometrium [9, 10] and  it is associated with abnormal 
prostaglandin-E2 and cytokine production [11]. Yet, the 
underlying molecular mechanics that may participate in 
each of these events is still poorly understood.
Up to 60% of the women affected by endometriosis pre-
sent characteristic symptoms such as dysmenorrhea, dys-
pareunia, dyschezia, dysuria and cyclic back pain, as well 
as cyclic and noncyclic lower abdominal pain [12]. How-
ever, recognition and conclusive diagnosis only occur on 
the average approximately 9  years following the begin-
ning of the disease [13]. Factors responsible for such a 
delayed diagnosis include asymptomatic course   the of 
disease, nonspecific symptoms and inconclusive find-
ings in non-invasive examinations. The current gold 
standard for the diagnosis of the disease combines lapa-
roscopic evaluation and biopsy of the visualized lesions 
[14]. Although laparoscopy is a minimally invasive proce-
dure, it requires general anesthesia and developed surgi-
cal skills, and it has a high procedural cost. In addition, 
laparoscopy is associated with the risk, although rare, of 
potential intraoperative or postoperative complications 
[15].
Early detection would allow individuals affected by 
the disease more options for treatment, i.e. making ear-
lier surgical treatment more effective and assist in the 
search for factors involved in pathogenesis. Even though 
the urgent need for early non-invasive diagnosis was 
well recognized over a half-century ago [16], no signifi-
cant contributions to endometriosis diagnosis have been 
made in this field.
Currently, no non-invasive imaging modalities that can 
be used to accurately diagnose endometriosis are avail-
able in clinical practice.
A recent Cochrane database systematic review [17] 
concluded that rectosigmoid endometriosis is the only 
site that could be accurately mapped by using trans-vag-
inal ultrasound (TVUS), trans-rectal ultrasound (TRUS), 
magnetic resonance imaging (MRI) or multi-detector 
computerized tomography enema (MDCT-e). Specifi-
cally for endometrioma, TVUS and MRI displayed suf-
ficient accuracy to suggest their utility as a replacement 
test. However, the data were too scarce to permit mean-
ingful conclusions. Instead of MRI, TVUS could be used 
clinically to identify additional anatomical sites of deep 
infiltrating endometriosis, thus facilitating preoperative 
planning.
To date none of the evaluated imaging modalities is 
able to detect overall pelvic endometriosis with enough 
accuracy to be suggested for replacing surgical diagnosis.
To date, several noninvasive biomarkers have been pro-
posed as an adjunct in diagnostics. Cancer antigen 125 
(CA 125) is the most widely used biomarker of endome-
triosis; however, despite the finding of higher CA 125 
levels in some women with endometriosis, CA 125 may 
be a poor biomarker because it does not perform well 
in the detection of the disease [18]. Diagnostic markers 
have been searched in peritoneal [19], follicular [20], and 
endometrial fluid [21], in urine [22], and in blood cells 
[23] however, no definite diagnostic biomarker is yet 
available [17].
It is widely accepted that eutopic endometrium from 
endometriosis patients differ from eutopic endometrium 
from healthy women. Recent studies reported that matrix 
metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor 
of matrix metalloproteinases (TIMP-1) and transforming 
growth factor-β2 (TGF-β2) express a tendency to higher 
gene expression in the eutopic endometrium of women 
with endometriosis [24]. Euctopic endometrioum from 
endometriosis patients expresses moreover different mi-
RNA profiles [25] and an aberrant DNA methylome [26].
In addition, because implants of endometriosis in the 
pelvic cavity release substances in the peritoneal fluid 
that bathe the ovary and enter the uterine cavity through 
the oviducts, endometriotic markers may influence the 
entire reproductive system, including the cervical mucus 
(CM). No studies have been performed up to now to ver-
ify the possibility of identifying non-invasive biomarkers 
of endometriosis in CM.
The development of high-throughput technologies, 
such as proteomics, has led to an early identification of 
the diseases by comparing the protein composition in 
diseased and normal tissues [27]. In a previous study we 
confirmed that CM is a source of protein biomarkes and 
identified the constitutive protein composition of CM 
of fertile women and the changes in the CM proteome 
throughout the menstrual cycle [28].
The aim of this study was to characterize the pattern of 
proteins involved in the pathophysiology of endometrio-
sis. This aim could be important to furtherly focus which 




Ten 30–40 year old infertile women, with ovarian endo-
metriotic cysts were enrolled. Ten fertile women, with no 
history of fertility problems and who had a term delivery 
within 1 year before the study served as control group.
The inclusion criterion was a maximum age of 40 years 
for both groups. A specific inclusion criterion for the 
patients with endometriosis was that the endometriosis 
diagnosis was obtained by videolaparoscopy and con-
firmed by histological exam of the endometiotic cyst.
The exclusion criteria for both groups were as fol-
lows: patients with a history of polycystic ovary syn-
drome, cancer, premature ovarian failure, or other 
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gynecologic factors leading to infertility that could affect 
folliculogenesis.
Cervical and vaginal swabs were obtained before sam-
ple collection to exclude cervical and vaginal infection. 
PAP tests and colposcopy were also performed before 
sample collection.
CM collection and sample preparation
Cervical mucus samples (n  =  1 per patient) were 
obtained by gentle aspiration from the cervical canal 
using a catheter for intrauterine insemination (Gynetics 
Medical Products, Achel, Belgium). Samples were col-
lected during the ovulation phase of the menstrual cycle. 
Ovulation was assessed by transvaginal sonography and 
confirmed by the measurement of midluteal serum pro-
gesterone levels.
The cervical mucus was collected in plastic tubes and 
mixed 1:1 (v/v) with aqueous trifluoroacetic acid solution 
(0.2% v/v) and centrifuged at 9200g for 10 min. The solu-
ble acidic fraction was stored at −80 °C until analysis. An 
aliquot of the soluble acidic fraction of each CM sample, 
corresponding to 40 µg of total protein (as measured by 
the Bradford assay), was mixed with 1  M ammonium 
bicarbonate pH 8.0 and reduced with 200  mM dithi-
othreitol (DTT 10 mM final, Sigma) for 5 min at 100 °C 
and 15  min at 50  °C, and then alkylated with 200  mM 
iodoacetamide (IAA 55 mM final, Sigma) in the dark at 
room temperature for 60  min. The samples were left to 
digest overnight at 37 °C by adding 100 mM ammonium 
bicarbonate (pH 8) with sequencing grade modified por-
cine trypsin (1:50, trypsin:protein concentration, Pierce 
Biotechnology). To stop the digestion, the samples were 
acidified with aqueous trifluoroacetic acid solution (0.2% 
v/v) and immediately frozen and lyophilized.
Proteomic analysis
The samples were resuspended in 40  μl of aqueous for-
mic acid solution (0.1% v/v) and equal protein quantity 
(8  μg) of each sample was analyzed using an Ultimate 
3000 RSLCnano equipped with an FLM-3000-Flow man-
ager module, and coupled using an Orbitrap Elite mass 
spectrometer (ThermoFisher, San Jose, CA). Separation 
experiments were performed using a Zorbax 300SB-C18 
column (3.5  mm particle diameter; column dimension 
1 mm i.d. 15 cm) (Agilent Technologies, Santa Clara, CA) 
using the following eluents: (A) 0.1% (v/v) aqueous formic 
acid and (B) acetonitrile:water 80:20 with 0.1% (v/v) aque-
ous formic acid. The applied gradient was linear from 0 
to 55% of solvent B in 60 min, at a flow rate of 50 μl/min. 
The Elite-Orbitrap mass spectrometer was operated in 
data-dependent mode in which each full MS scan (60 000 
resolving power) was followed by MS/MS scans where the 
five most intense multiple-charged ions were dynamically 
selected and fragmented by collision-induced dissociation 
(CID) at a normalized collision energy of 35%. Samples 
were analyzed individually; proteomic analysis was per-
formed at the same time for all samples, while data analy-
sis was subsequently performed.
Data analysis
Tandem mass spectra were analysed using the Thermo 
Proteome Discoverer 1.4 software, and the SEQUEST 
cluster (University of Washington, Seattle, WA, licensed 
by Thermo Electron Corp) as the search engine against 
UniProtKb/Swiss-Prot protein knowledgebase release 
2015-10: 20196 Homo Sapiens protein database.
In order to obtain a reliable identification of the pep-
tides, the following filters were used: high value peptide 
confidence and false discovery rate (FDR) of 5%.
Data were searched for three missed cleavages, fixed 
carbamidomethylation of cysteines and the oxidation of 
methionines as variable modification.
The label-free quantification of common proteins was 
performed via Precursor Ions Area Detector Node dur-
ing the bioinformatic analysis using Proteome Discoverer 
software. This quantification method was used to obtain 
an idea of the relative quantities of all peptides in a sam-
ple. The Proteome Discoverer application calculates pep-
tide areas during processing, using them to automatically 
calculate protein areas for the proteins in the report. It 
calculates the area of any given protein as the average of 
the three most abundant distinct peptides identified in 
the protein.
Results are reported as average ±  standard deviation. 
Statistical analysis was carried out with SPSS v17.0 (IBM 
Corp., Armonk,NY, USA). All data were first analyzed 
for normality of distribution using the Kolmogorov–
Smirnov test of Normality. Since data were not normally 
distributed, the appropriate non-parametric (Mann–
Whitney) test was used to assess significance of the dif-
ferences between groups. p value <0.05 was considered as 
significant.
For the aim of this study, we considered the panel of 
proteins exclusively identified in the endometriosis group 
and in the control group. Moreover we evaluated the 
proteins significantly increased or reduced according to 
abundance index in the endometriosis versus the control 
group.
Results
Protein identification led to the characterization of a 
range of 44–140 different proteins per sample in the 
endometriosis group and 91–126 proteins in the control 
group.
All the proteins we identified in the endometriosis 
group have been detected in the control group.
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Six proteins were quantitatively increased in endome-
triosis, as reported in Fig. 1 and almost all are involved in 
the inflammatory pattern.
Nine proteins were quantitatively reduced in endo-
metriosis, as reported in Fig.  2, including some pro-
teins related with local innate immunity (CRISP-3 and 
Pglyrp1) and protection against oxidative stress (HSPB1).
Additional file  1: Table S1 reports the identified pro-
teins in the two groups.
Table 1 reports the mean values of the abundance index 
for each protein in the two groups, the number of sam-
ples in which the proteins have been detected in patients 
and controls and if the protein was or not previously 
reported as a marker of endometriosis.
Fifteen proteins were not detected in endometriosis 
samples compared to controls (Table  2) including some 
proteins involved in antimicrobial activity (SLURP1 and 
KLK13) or previously reported as related to seminal 
plasma liquefaction and male fertility (KLK13).
Discussion
In the postgenomic era, proteomic technology has rap-
idly developed and it has become a powerful tool in the 
research of human physiology, in particular in biologi-
cal fluids, characterizing the comprehensive proteomic 
composition and identifying potential novel biomarkers 
for diagnosis, prognosis and therapy in different clinical 
aspects, including reproduction [29]. Cervical mucus is 
a biofluid, representing a source of putative biomarkers 
for female genital tract diseases. The proteomic compo-
sition of cervical mucus is less complex when compared 
to plasma and urine, but few studies investigated cervical 
mucus composition in physiological conditions [28, 30] 
and no studies have been reported up to now concern-
ing the identification of CM biomarkers for genital tract 
diseases.
We studied for the first time CM protein composition 
with the aim of identifying some proteins involved in the 
pathophysiology of endometriosis. The integration of 
high-resolution MS proteomic techniques and bioinfor-
matic analysis permitted the identification of a pattern of 
proteins which could represent a molecular signature of 
endometriosis.
Overexpressed proteins
Six proteins resulted overexpressed in endometriosis: 
4 out to these 6 proteins are related with inflammation, 
including polymeric immunoglobulin receptor (pIgR), 
Alpha-1-acid glycoprotein 2, Metalloproteinase inhibitor 
1 and Neutrophil gelatinase-associated lipocalin. Inflam-
matory processes have a crucial role in the pathogen-
esis of endometriosis [31] as suggested by the abnormal 
Fig. 1 Protein abundance in endometriosis and controls—proteins increased in patients with endometriosis
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levels of immune system cells, including macrophages 
[32], dendritic cells [33] and natural killer cells [34], 
within the female reproductive tract reported in patients 
with endometriosis. These cells are unable to completely 
eliminate ectopic endometrial cells. Moreover, immune 
system cells were found to be dysfunctional in endome-
triosis [34, 35]. Complicated reactions may occur due 
to endometriosis-induced secretion of cytokines [36], 
chemokines [37], nitric oxide [38], immunoglobulins 
[39], and immune cells [32–35]. Triggered immune reac-
tions signify the host recognition of infectious agents, 
but, if pathogens are not swiftly recognized, immune 
reactions necessary to fight infections do not occur. Pre-
vious data reported an higher prevalence of endometritis 
in women with endometriosis [40], which may represent 
an adjunctive mechanisms to explain the decrease of fer-
tility in these women.
The overexpressed proteins verified in this study con-
firm the presence of inflammatory protein pattern in CM 
of patients with endometriosis, even if vaginal and cer-
vical swabs excluded vaginal and cervical infection in all 
patients.
In particular, Polimeric Immunoglobulin Recep-
tor (pIgR) plays an important role in mucosal immune 
systems, since it binds and transports IgA in different 
mucosal tissues [41]. Previous data reported that IgA and 
IgG are differentially associated with the types of mucus 
of the female reproductive tract, since both IgA and IgG 
are stably associated with cervical mucus, but only IgG 
is associated with cervicovaginal mucus [42]. Antibod-
ies can bind tightly to mucus, where they play a signifi-
cant role in the fortification of the mucus barriers of the 
female reproductive tract.
Orosomucoid 2 (ORM2), also known as alpha 1 acid 
glycoprotein 2, is a type of acute-phase protein consid-
ered an anti-inflammatory and immunomodulatory 
factor due to its anti-neutrophil and anti-complement 
activity [43].
Tissue inhibitors of metalloproteinases (TIMP) are the 
inhibitors of matrix metalloproteinases. Expression of 
matrix metalloproteinases (MMPs) and their inhibitors 
(tissue inhibitors of metalloproteinases, TIMPs) is report-
edly involved in the pathogenesis and pathophysiology of 
endometriosis. The MMPs and TIMPs are synthesized 
and secreted by both eutopic and ectopic endometrium 
in both the human and the rat [44, 45]. TIMP1 represents 
at least 10–15% of the proteins secreted into the perito-
neal cavity by both rat implants and human endometri-
otic lesions [46]. Previous data reported that an excessive 
TIMP1 secretion in endometriosis was deleterious to 
Fig. 2 Protein abundance in endometriosis and controls—proteins decreased in patients with endometriosis
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ovulation and embryo development [47]. There are some 
literature reports about the expression of TIMP in CM, 
linking the expression of metalloproteinases-TIMP sys-
tems in the cervical mucus plug during pregnancy with 
the proteolytic activity in connection with term and pre-
term birth [48]. We previously reported that TIMP-1 is a 
marker of pre-ovulatory CM in fertile patients that might 
be associated with the inhibition of proteolitic activity, 
which leads to the liquefaction of CM in the ovulatory 
phase [28]. In patients with endometriosis, the higher 
expression of TIMP-1 during ovulatory phase might con-
tribute in inhibiting the proteolitic activity and the lique-
faction of CM, which is essential for CM permeability to 
spermatozoa.
Neutrophil gelatinase-associated lipocalin (NGAL) 
was previously identified by a proteomic approach as 
a marker of neutrophil activity in cervical–vaginal fluid 
[49]. NGAL has been previously reported to be elevated 
in the urine of patients with endometriosis [50].
In conclusion, the proteic pattern of abacterial cervical 
inflammation associated with endometriosis might both 
reflect the dysfunctional immune pattern of endometrio-
sis and represent a link with endometriosis-associated 
infertility.
Down‑expressed proteins in endometriosis
Nine proteins were reduced in endometriosis, including 
Azurocidin 1, an important inflammatory mediator [51], 
Table 2 Proteins not detected in CM of patients with endometriosis
Accession Description Σ coverage Σ# proteins Σ# unique 
peptides





MW (kDa) X score (mean) Calc. pI




52.43 1 2 2 8 11.2 12.88 5.33




26.53 1 3 3 8 21.7 11.65 8.59
P02671 Fibrinogen alpha 
chain
24.71 1 12 12 8 94.9 26.72 6.01
P10153 Non-secretory 
ribonuclease





21.97 1 4 4 10 35.9 25.57 7.75
P12724 Eosinophil cati-
onic protein




19.90 1 3 3 8 23.0 9.13 5.21
O75015 Low affinity 
immunoglob-
ulin gamma Fc 
region recep-
tor III-B




14.76 1 3 3 8 36.7 9.94 8.27
P32926 Desmoglein-3 10.01 1 7 7 8 107.5 43.29 5.00
Q02487 Desmocollin-2 8.88 1 4 4 8 99.9 29.56 5.34
P07477 Trypsin-1 7.29 1 2 2 9 26.5 7.55 6.51
P0C0L4 Complement 
C4-A
1.95 2 2 2 9 192.7 9.55 7.08
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cysteine-rich secretory protein 3 (CRISP-3) and Heat 
shock protein beta-1 (HSPB1).
CRISP-3 is present in exocrine secretions and in secre-
tory granules of neutrophilic granulocytes and is believed 
to play a role in local innate immunity, which is depressed 
in patients with endometriosis [52]. Furthermore CRISP 
proteins have been reported to exert a role in sperm-
oocyte chemotaxis both in frogs and mouse [53].
We observed a reduction of the antioxidant protein 
HSPB1. It is a small heat shock protein involved in many 
cellular processes, which protects cells against oxidative 
stress [54]. Endometriosis has been previously reported 
to be linked with oxidative stress, altering follicular 
microenvironment and oocyte quality [55, 56]. Further 
studies will clarify if endometriosis is associated with oxi-
dative stress pattern in cervical mucus and its correlation 
with female infertility.
Proteins not detected in endometriosis samples
Fifteen proteins were not detected in endometriosis sam-
ples, including some proteins involved in antimicrobial 
activity and possibly associated with fertility.
Human tissue kallikreins are members of a large multi-
gene family of 15 serine proteases. The human kallikrein 
13 gene (KLK13) codes for a trypsin-like, secreted ser-
ine protease (hK13). It was reported to be expressed in 
various tissues [57] and found at high concentrations in 
secreted biological fluids such as seminal plasma, amni-
otic fluid, milk of lactating women, follicular fluid, and 
cerebrospinal fluid [58], but up to now not reported as 
expressed in cervical mucus. Previous studies reported 
that kallikreins are important in the control of sperm 
liquefaction and sperm motility [59]. Further studies are 
needed to clarify the functional role of hK13 in cervi-
cal mucus and the molecular significance of its absence 
in endometriosis. We may speculate that the absence 
KLK13 in endometriosis could have a role in infertility.
We observed the absence of secreted Ly6/urokinase-
type plasminogen activator receptor-related protein 
(SLURP) 1 and 3 proteins. SLURP1 belongs to the Ly6/
uPAR superfamily of proteins that participate in signal 
transduction, immune activation, and cell adhesion [60]. 
It is expressed in a variety of cells including immune cells 
[61], bronchial epithelial cells [62], primary sensory neu-
rons [63], skin, gums, stomach, trachea and esophagus 
[64], oral keratinocytes [65], cornea [66] and exocervix 
[64]. In corneal tissue it was reported that SLURP1 is a 
soluble scavenger of urokinase-type plasminogen activa-
tor (uPAR) and of its soluble form (suPAR) [67]. Numer-
ous studies have shown that systemic soluble urokinase 
plasminogen activator receptor (suPAR) levels increase in 
various inflammatory diseases. In recent years it has been 
considered a reliable diagnostic and prognostic marker of 
systemic inflammation. uPAR and its ligand are involved 
in numerous physiological and pathological pathways, 
which include the plasminogen activating pathway, regu-
lation of pericellular proteolysis, modulation of cell adhe-
sion, migration, and proliferation through interactions 
with proteins present in the extracellular matrix [68]. In 
a previous study we demonstrated that suPAR might rep-
resent an inflammatory marker in reproduction for the 
male accessory glands [69]. In cervical mucus of patients 
with endometriosis we reported the absence of the scav-
enger proteins SLURP-1 and SLURP-3. We may speculate 
that endometriosis might cause an increase in uPAR acti-
vation and suPAR production, which are associated with 
an inflammatory pattern. Further studies are needed to 
confirm these data.
In CM of patients with endometriosis we reported the 
differential expression of Peptidoglycan recognition pro-
tein 1 (Pglyrp1). Pglyrps are a family of pattern-recogni-
tion proteins that mediate innate immunity to bacterial 
pathogens via binding peptidoglycan moieties [70]. Pre-
vious literature data confirmed that subclinical uterine 
infection and endometritis are more frequent in women 
with endometriosis versus controls [40]. The absence 
of Pglyrp1 might represent a molecular mechanism 
involved in the higher prevalence of infections in patients 
with endometriosis.
Conclusions
We identified in the CM of patients affected by endo-
metriosis some proteins which are mainly related to the 
pathogenesis of inflammation and the induction of a 
dysfunctional immune system. These data are consistent 
with previous reports about endometriosis as a chronic 
inflammatory disease.
Despite the limitations of the study, which was per-
formed using fertile women and not on patients with 
endometriosis-like symtoms, without endometriosis at 
laparoscopic and histological examination, as control 
group, this is the first application of high resolution mass 
spectrometry—based proteomics aimed to reveal an 
array of proteins in CM which might represent a molecu-
lar signature of endometriosis. Our data confirm at the 
same time both the inflammatory pattern and the impair-
ment of the natural immune system in the CM of patients 
affected by endometriosis.
Additional file
Additional file 1: Table S1. Identified proteins in CM in the group of 
controls and in patients affected by endometriosis.
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